{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:33:20Z","timestamp":1786545200903,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1038\/ajg.2012.19","type":"journal-article","created":{"date-parts":[[2012,3,20]],"date-time":"2012-03-20T09:01:02Z","timestamp":1332234062000},"page":"522-530","source":"Crossref","is-referenced-by-count":57,"title":["Efficacy of Twice-Daily Rabeprazole for Reflux Esophagitis Patients Refractory to Standard Once-Daily Administration of PPI: The Japan-Based TWICE Study"],"prefix":"10.14309","volume":"107","author":[{"given":"Yoshikazu","family":"Kinoshita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Hongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl","key":"R1-8-20210210","first-page":"25","article-title":"Epidemiology of reflux disease and CLE in East Asia.","volume":"38","author":"Hongo","year":"2003","journal-title":"J Gastroenterol"},{"key":"R2-8-20210210","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.1440-1746.2003.02932.x","article-title":"Clinical characteristics of Japanese reflux esophagitis patients as determined by Los Angeles classification.","volume":"18","author":"Inamori","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"R3-8-20210210","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1046\/j.1440-1746.2001.02408.x","article-title":"Role of hiatus hernia and gastric mucosal atrophy in the development of reflux esophagitis in the elderly.","volume":"16","author":"Amano","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"R4-8-20210210","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1046\/j.1440-1746.2001.02618.x","article-title":"Influence of Helicobacter pylori infection on the prevalence of reflux esophagitis in Japanese patients.","volume":"16","author":"Fujishiro","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"R5-8-20210210","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2036.1999.00438.x","article-title":"Double-blind, placebo-controlled comparison of rabeprazole 20mg vs omeprazole 20mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease.","volume":"13","author":"Dekkers","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-8-20210210","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/j.1440-1746.2006.04190.x","article-title":"Therapeutic effects of 10mgday rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism.","volume":"21","author":"Ariizumi","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"R7-8-20210210","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1572-0241.2002.05532.x","article-title":"Esomeprazole (40mg) compared with lansoprazole (30mg) in the treatment of erosive esophagitis.","volume":"97","author":"Castell","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R8-8-20210210","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1046\/j.1365-2036.2000.00856.x","article-title":"Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial.","volume":"14","author":"Kahrilas","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-8-20210210","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s00535-006-1756-z","article-title":"Treatment of proton pump inhibitor-resistant patients with gastroesophageal reflux disease.","volume":"41","author":"Kinoshita","year":"2006","journal-title":"J Gastroenterol"},{"key":"R10-8-20210210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2036.2005.02531.x","article-title":"Systematic review: systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux diseasewhere next?","volume":"22","author":"Fass","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R11-8-20210210","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/gut.2007.145581","article-title":"Management of heartburn not responding to proton pump inhibitors.","volume":"58","author":"Fass","year":"2009","journal-title":"Gut"},{"issue":"Suppl 199","key":"R12-8-20210210","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/00365529309098350","article-title":"Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases.","volume":"28","author":"Dimenas","year":"1993","journal-title":"Scand J Gastroenterol"},{"key":"R13-8-20210210","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","article-title":"The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus.","volume":"101","author":"Vakil","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R15-8-20210210","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1572-0241.2005.41217.x","article-title":"Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease.","volume":"100","author":"DeVault","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R16-8-20210210","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1046\/j.1440-1746.2003.03190.x","article-title":"Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.","volume":"18","author":"Adachi","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"R17-8-20210210","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2036.2002.01181.x","article-title":"Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.","volume":"16","author":"Robinson","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R18-8-20210210","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1365-2036.2002.01207.x","article-title":"A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.","volume":"16","author":"Holtmann","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R20-8-20210210","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.1365-2036.2003.01821.x","article-title":"Rabeprazole 10mg twice daily is superior to 20mg once daily for night-time gastric acid suppression.","volume":"19","author":"Shimatani","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-8-20210210","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00535-003-1157-0","article-title":"Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens.","volume":"38","author":"Adachi","year":"2003","journal-title":"J Gastroenterol"},{"key":"R22-8-20210210","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.dld.2006.06.002","article-title":"Acid-suppressive effects of rabeprazole: comparing 10 and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers.","volume":"38","author":"Shimatani","year":"2006","journal-title":"Dig Liver Dis"},{"key":"R23-8-20210210","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1080\/003655200453566","article-title":"Rabeprazole, 20mg once daily or 10mg twice daily, is equivalent to omeprazole, 20mg once daily, in the healing of erosive gastro-oesophageal reflux disease.","volume":"35","author":"Delchier","year":"2000","journal-title":"Scand J Gastroenterol"},{"key":"R24-8-20210210","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/j.1365-2036.2006.03140.x","article-title":"A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study.","volume":"24","author":"Miki","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"RU25-8-20210210","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1001\/jama.292.23.2890","article-title":"Dose this woman have osteoporosis?","volume":"292","author":"Amanda","year":"2004","journal-title":"JAMA"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg201219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg201219","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg201219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201204000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:37:57Z","timestamp":1786541877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201204000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2012.19","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}